Compare CMT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMT | CGEN |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | Israel |
| Employees | 1239 | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.1M | 201.8M |
| IPO Year | 1996 | 2001 |
| Metric | CMT | CGEN |
|---|---|---|
| Price | $22.54 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.80 |
| AVG Volume (30 Days) | 33.0K | ★ 238.6K |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $284,290,000.00 | N/A |
| Revenue This Year | $0.58 | N/A |
| Revenue Next Year | $8.99 | $6.65 |
| P/E Ratio | $49.24 | ★ N/A |
| Revenue Growth | ★ 5.49 | N/A |
| 52 Week Low | $17.36 | $1.43 |
| 52 Week High | $28.69 | $3.24 |
| Indicator | CMT | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 50.37 |
| Support Level | $18.22 | $1.98 |
| Resistance Level | $24.13 | $2.20 |
| Average True Range (ATR) | 0.96 | 0.09 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 52.33 | 77.19 |
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.